Cantor Fitzgerald Reiterates Overweight on Poseida Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on Poseida Therapeutics (NASDAQ:PSTX) and maintained a $14 price target.
October 10, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $14.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Poseida Therapeutics. The maintained price target of $14 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100